Jardiance 10mg Empagliflozin Tablets 30s

Jardiance 10mg Empagliflozin Tablets 30s is a prescription medicine containing empagliflozin 10mg in each film-coated tablet. Empagliflozin belongs to a class of medicines known as sodium-glucose co-transporter 2 inhibitors, commonly abbreviated as SGLT2 inhibitors.

Jardiance 10mg may be prescribed for type 2 diabetes mellitus, heart failure and chronic kidney disease. It may also be used to reduce cardiovascular-death risk in selected adults with type 2 diabetes and established cardiovascular disease.

The approved indication, treatment duration and monitoring requirements depend on the patient’s age, diagnosis, kidney function, hydration status, concurrent medicines and overall clinical condition.

Jardiance is not intended for self-selection, general weight-loss use, treatment of type 1 diabetes or treatment of diabetic ketoacidosis.

Jardiance 10mg Empagliflozin Product Information

What Is Jardiance 10mg Used For?

Jardiance 10mg may be prescribed for several product-specific indications. The medicine should only be used for the indication stated in the patient’s prescription.

Type 2 Diabetes Mellitus

Jardiance is used with an appropriate diet and physical-activity programme to improve blood-glucose control in adults and children aged 10 years and above with type 2 diabetes mellitus.

It may be prescribed:

• As monotherapy when metformin is considered inappropriate because of intolerance
• Together with metformin or another oral diabetes medicine
• Together with insulin when additional glycaemic control is required
• As part of a broader diabetes and cardiovascular-risk management plan

When Jardiance is used with insulin or a sulfonylurea, the doctor may review the dosage of those medicines because the risk of hypoglycaemia may increase.

Cardiovascular-Risk Reduction

Jardiance may be prescribed to reduce the risk of cardiovascular death in selected adults with type 2 diabetes mellitus and established cardiovascular disease.

This indication does not mean that Jardiance replaces other cardiovascular medicines, blood-pressure management, lipid-lowering treatment or lifestyle measures.

Heart Failure

Jardiance 10mg may be prescribed for adults with heart failure to reduce the risk of cardiovascular death and hospitalisation for heart failure.

Heart failure occurs when the heart cannot pump blood around the body as effectively as required. Symptoms may include:

• Breathlessness
• Reduced exercise tolerance
• Fatigue or weakness
• Swelling of the ankles or legs
• Rapid weight increase caused by fluid retention

Jardiance is used as part of an overall heart-failure treatment plan. It should not replace another prescribed heart medicine unless the treating doctor provides specific instructions.

Chronic Kidney Disease

Jardiance 10mg is also indicated for adults with chronic kidney disease.

Chronic kidney disease is a long-term condition in which kidney function declines or the kidneys show evidence of continuing damage. Treatment suitability depends on kidney function, the underlying kidney condition and the patient’s complete treatment plan.

The Malaysian approved information states that initiation is not recommended when estimated glomerular filtration rate is below 20mL/min/1.73m² because clinical experience is limited.

Use in Children and Adolescents

Jardiance is approved in Malaysia for improving glycaemic control in children aged 10 years and above with type 2 diabetes mellitus.

The recommended starting dose for this indication is 10mg once daily. A doctor may increase the dose to 25mg once daily when 10mg is tolerated and additional glycaemic control is required.

No data are available for children below 10 years old or children with an estimated glomerular filtration rate below 60mL/min/1.73m².

The safety and effectiveness of Jardiance for heart failure or chronic kidney disease have not been established in patients below 18 years old.

How Jardiance Works

SGLT2 proteins in the kidneys normally return filtered glucose and sodium to the bloodstream.

Empagliflozin blocks SGLT2 activity. This allows additional glucose, sodium and water to leave the body through the urine.

In patients with type 2 diabetes, this mechanism helps lower blood-glucose levels. Empagliflozin also produces cardiovascular and kidney effects that support its approved use in selected adults with heart failure and chronic kidney disease.

How to Take Jardiance 10mg

• Take Jardiance exactly as prescribed by the treating doctor.
• The usual reference dose is one 10mg tablet once daily.
• Swallow the tablet whole with water.
• Jardiance may be taken with or without food.
• Take the tablet at approximately the same time each day.
• Do not increase, reduce or stop treatment without professional advice.
• Do not change between the 10mg and 25mg strengths without a new medical instruction.
• Continue any diet, physical-activity, blood-glucose monitoring or fluid-management plan recommended by the healthcare professional.

For type 2 diabetes, the dose may be increased to 25mg once daily in appropriate patients who tolerate 10mg and require additional glycaemic control.

The recommended dose for heart failure and chronic kidney disease is 10mg once daily.

What to Do If a Dose Is Missed

Take the missed dose as soon as it is remembered. Do not take a double dose on the same day to compensate for a forgotten tablet.

Consult a doctor or pharmacist if several doses have been missed or there is uncertainty about when to restart treatment.

Monitoring During Treatment

A healthcare professional may monitor:

• Kidney function
• Blood-glucose levels and HbA1c in patients with diabetes
• Blood pressure
• Hydration and fluid status
• Symptoms of urinary or genital infection
• Signs of diabetic ketoacidosis
• Heart-failure symptoms where applicable
• Kidney-disease progression where applicable
• Frequency of hypoglycaemia when insulin or a sulfonylurea is used

Patients should attend all laboratory tests and follow-up appointments arranged by the treating healthcare professional.

Important Safety Information

• Jardiance is a prescription medicine and should not be shared with another person.
• It should not be used to treat type 1 diabetes.
• It must not be used to treat diabetic ketoacidosis.
• It is not approved as a general weight-loss medicine.
• Tell the doctor about kidney disease, liver disease, low blood pressure or recurrent urinary infections.
• Tell the doctor about severe vomiting, diarrhoea, fever, reduced food intake or dehydration.
• Maintain appropriate fluid intake unless a healthcare professional has advised fluid restriction.
• Inform the treating team before major surgery, prolonged fasting or hospitalisation for a serious illness.
• Tell the prescriber about insulin, sulfonylureas, diuretics, lithium and all other medicines being used.

Diabetic Ketoacidosis Warning

SGLT2 inhibitors, including empagliflozin, have been associated with diabetic ketoacidosis, commonly abbreviated as DKA. DKA is a serious and potentially life-threatening condition caused by excessive ketone accumulation.

DKA associated with an SGLT2 inhibitor may occur even when the blood-glucose level is not extremely high.

Stop taking Jardiance and seek urgent medical attention if symptoms occur such as:

• Nausea or vomiting
• Abdominal pain
• Loss of appetite
• Excessive thirst
• Rapid or unusually deep breathing
• Difficulty breathing
• Confusion
• Unusual tiredness or sleepiness
• Sweet or unusual-smelling breath

The risk of DKA may increase during severe illness, dehydration, prolonged fasting, major surgery, excessive alcohol intake, sudden insulin reduction or medical conditions that increase insulin requirements.

Jardiance may need to be temporarily interrupted before major surgery or during a serious acute illness. The treating healthcare professional should provide instructions on when treatment can be restarted.

Dehydration and Low Blood Pressure

Empagliflozin increases glucose, sodium and fluid removal through the urine. This may cause dehydration, reduced circulating fluid volume or low blood pressure in susceptible patients.

The risk may be greater in:

• Adults aged 75 years and above
• Patients taking diuretics
• Patients taking several blood-pressure medicines
• Patients who already have low blood pressure
• Patients experiencing vomiting or diarrhoea
• Patients with fever, heavy sweating or reduced fluid intake

Possible symptoms include dizziness, faintness, weakness, dry mouth, unusual thirst or reduced urine output.

Seek medical advice if significant fluid loss or symptoms of dehydration occur. Temporary interruption of treatment may be required until the patient is stable and adequately hydrated.

Genital and Urinary Infections

Empagliflozin increases the amount of glucose passed through the urine. This may increase the likelihood of certain genital fungal infections and urinary tract infections.

Possible symptoms include:

• Pain or burning during urination
• Frequent or urgent urination
• Fever or chills
• Back or side pain
• Blood in the urine
• Genital itching, redness or irritation
• Unusual genital discharge or odour

Obtain prompt medical advice if these symptoms occur. A severe urinary infection, kidney infection or urosepsis requires urgent assessment.

Fournier’s Gangrene Warning

A rare but serious infection known as necrotising fasciitis of the perineum or Fournier’s gangrene has been reported in patients taking SGLT2 inhibitors.

Seek urgent medical attention for pain, tenderness, redness or swelling around the genitals or the area between the genitals and anus, especially when accompanied by fever or feeling generally unwell.

Jardiance should be discontinued and urgent medical and surgical treatment initiated when Fournier’s gangrene is suspected.

Kidney Inflammation Warning

Tubulointerstitial nephritis, an inflammatory kidney condition, has been reported in association with empagliflozin.

A healthcare professional should consider this condition if kidney function progressively declines after treatment begins or if symptoms occur such as:

• A significant reduction in urine output
• Swelling or fluid retention
• Unexplained fever or rash
• Persistent nausea
• Unusual weakness
• Unexpected deterioration in kidney-function test results

Patients should not independently stop kidney-protective treatment merely because they have chronic kidney disease. Any suspected medicine-related kidney reaction requires professional assessment.

Hypoglycaemia

Jardiance used without insulin or a sulfonylurea generally has a relatively low risk of causing hypoglycaemia. The risk increases when it is combined with insulin or medicines that stimulate insulin release.

Possible symptoms of low blood glucose include:

• Shaking or sweating
• Hunger
• Dizziness
• Headache
• Blurred vision
• Rapid heartbeat
• Anxiety, confusion or unusual behaviour

The doctor may need to reduce the insulin or sulfonylurea dose. Patients should follow their individual hypoglycaemia-management plan.

Possible Side Effects

Not everyone experiences side effects. Possible effects associated with empagliflozin include:

• Genital fungal infection
• Urinary tract infection
• Passing urine more frequently
• Increased urine volume
• Thirst
• Dizziness or low blood pressure
• Skin rash or itching
• Temporary changes in kidney-function test results
• Hypoglycaemia when combined with insulin or a sulfonylurea

Persistent, worsening or troublesome side effects should be discussed with a doctor or pharmacist.

Serious Symptoms Requiring Medical Attention

Seek prompt or urgent medical attention if any of the following occurs:

• Symptoms of diabetic ketoacidosis
• Severe dehydration, fainting or very low blood pressure
• Fever with painful urination or back pain
• Severe genital or perineal pain, redness or swelling
• Swelling of the face, lips, tongue or throat
• Difficulty breathing or swallowing
• A significant or unexplained decline in urine output
• A severe or widespread skin reaction
• Another serious or unexpected reaction

Kidney Function Considerations

Kidney function should be assessed according to the indication and the patient’s clinical condition.

The Malaysian approved chronic-kidney-disease information states that initiation is not recommended when estimated glomerular filtration rate is below 20mL/min/1.73m² because experience is limited.

In patients with type 2 diabetes, the glucose-lowering effectiveness of empagliflozin decreases as kidney function declines. Additional glucose-lowering treatment may be required even when Jardiance is continued for a heart or kidney indication.

Patients should not independently stop Jardiance solely because they have chronic kidney disease. Treatment decisions must be based on the approved indication, kidney function and professional clinical assessment.

Medicine Interactions

Tell the doctor and pharmacist about all prescription medicines, non-prescription products, traditional medicines and supplements being used.

Medicines requiring particular consideration include:

• Insulin: combined use may increase the risk of hypoglycaemia.
• Sulfonylureas: medicines such as gliclazide or glimepiride may increase hypoglycaemia risk.
• Diuretics: combined use may increase fluid loss, dehydration and low blood pressure.
• Other blood-pressure medicines: additional blood-pressure reduction may occur.
• Lithium: empagliflozin may increase urinary lithium elimination and reduce serum lithium concentrations. Additional monitoring may be required.
• Other glucose-lowering medicines: the complete diabetes treatment plan may need adjustment.

Do not start, stop or change another medicine without consulting the treating doctor or pharmacist.

Pregnancy and Breastfeeding

Patients who are pregnant, planning a pregnancy or think they may be pregnant should inform their doctor before taking Jardiance.

Use during pregnancy is generally avoided because adequate human data are unavailable and SGLT2 inhibition may affect kidney development later in pregnancy.

Jardiance should not normally be used during breastfeeding because a risk to the nursing infant cannot be excluded.

Urine Glucose Tests

Because Jardiance removes glucose through the urine, urine tests will normally show glucose while the medicine is being taken.

This is an expected effect of the medicine and does not by itself mean that treatment is failing. Blood-glucose and HbA1c testing should be interpreted according to the patient’s monitoring plan.

Storage Instructions

• Store according to the conditions printed on the Malaysian carton and approved package insert.
• Keep the tablets in their original blister packaging until required.
• Protect from excessive heat and moisture.
• Keep out of reach of children.
• Do not use tablets that appear wet, damaged, discoloured or deteriorated.
• Do not use after the expiry date printed on the supplied packaging.
• Product packaging, registration number, manufacturing site, batch number and expiry date may vary between supplied batches.

Frequently Asked Questions

What is the active ingredient in Jardiance 10mg?

Each Jardiance 10mg film-coated tablet contains empagliflozin 10mg.

What type of medicine is Jardiance?

Jardiance is a sodium-glucose co-transporter 2 inhibitor, commonly abbreviated as an SGLT2 inhibitor.

What is Jardiance 10mg used for?

Jardiance 10mg may be prescribed for type 2 diabetes mellitus, heart failure and chronic kidney disease. It may also reduce cardiovascular-death risk in selected adults with type 2 diabetes and established cardiovascular disease.

Is Jardiance only a diabetes medicine?

No. Jardiance also has approved indications for heart failure and chronic kidney disease in adults.

Can patients without diabetes take Jardiance?

Yes. Jardiance may be prescribed to selected adults with heart failure or chronic kidney disease even when they do not have type 2 diabetes.

Can children take Jardiance?

Jardiance is approved for improving glycaemic control in children aged 10 years and above with type 2 diabetes. It is not established for paediatric heart failure or chronic kidney disease.

How does Jardiance lower blood glucose?

Empagliflozin blocks SGLT2 proteins in the kidneys, allowing additional glucose to leave the body through the urine.

How often is Jardiance 10mg taken?

The usual reference dose is one 10mg tablet once daily. Patients must follow the dosage stated on their individual prescription and dispensing label.

Can Jardiance be taken with food?

Yes. Jardiance may be taken with or without food and should be swallowed with water.

What is the difference between Jardiance 10mg and 25mg?

Both strengths contain empagliflozin. The 25mg strength may be used for additional glycaemic control in appropriate patients who tolerate the 10mg dose. The recommended dose for heart failure and chronic kidney disease is 10mg once daily.

Is Jardiance a weight-loss medicine?

No. Jardiance is not approved as a general weight-loss medicine. Any change in body weight during treatment should be discussed with the treating healthcare professional.

Can Jardiance be used for type 1 diabetes?

No. Jardiance should not be used to treat type 1 diabetes because of the increased risk of diabetic ketoacidosis.

Can Jardiance treat diabetic ketoacidosis?

No. Jardiance must not be used to treat diabetic ketoacidosis. SGLT2 inhibitors may themselves increase DKA risk in certain circumstances.

Can Jardiance cause low blood glucose?

Empagliflozin used alone has a relatively low hypoglycaemia risk. The risk increases when Jardiance is combined with insulin or a sulfonylurea.

Why can Jardiance cause genital infections?

Jardiance increases the amount of glucose removed through the urine. Additional glucose around the urinary and genital areas may increase the likelihood of certain fungal or urinary infections.

Why might Jardiance be stopped before surgery?

Major surgery, fasting and serious illness may increase the risk of diabetic ketoacidosis. The treating team may temporarily interrupt Jardiance until the patient is clinically stable.

Will urine test positive for glucose while taking Jardiance?

Yes. Glucose in the urine is an expected result of empagliflozin’s mechanism of action.

Is Jardiance 10mg a prescription medicine in Malaysia?

Yes. Jardiance is a prescription medicine and should only be supplied and used according to a valid prescription and professional instructions.

What is the Malaysian registration number for Jardiance 10mg?

The principal Malaysian registration number is MAL15125055ARZ. A supplemental manufacturing presentation is registered as MAL24026012ACSZ. Verify the exact number printed on the supplied carton.

Who manufactures Jardiance 10mg?

Registered Malaysian manufacturing presentations include Boehringer Ingelheim Seiyaku Co. Ltd., Japan, and Rottendorf Pharma GmbH, Germany. The exact manufacturer should be verified on the supplied carton.

How many tablets are supplied in one pack?

The P-Hub listing contains 30 film-coated tablets, supplied as three blister strips of ten tablets.

Can pharmacies request Jardiance through P-Hub?

Jardiance 10mg Empagliflozin Tablets 30s is listed in the P-Hub B2B catalogue for approved pharmacy members. Quotation, ordering eligibility and supply are subject to P-Hub membership requirements, prescription medicine controls and current stock availability.

Prescription Medicine Notice

Jardiance 10mg is a prescription medicine. It should only be supplied, dispensed and used according to applicable Malaysian requirements and the instructions of a registered doctor or pharmacist.

The information on this page is provided for pharmacy catalogue and professional product-reference purposes. It does not replace an individual medical assessment, prescription, approved Malaysian package insert or advice from a qualified healthcare professional.

Product appearance, packaging, registration number, manufacturing site, batch number, availability and expiry date may vary. Verify all information on the physical product packaging and approved insert before dispensing or use.

Product Information Sources

• Boehringer Ingelheim Malaysia – Jardiance Prescribing Information
  
• NPRA Malaysia – Jardiance Type 2 Diabetes Paediatric Indication
  
• NPRA Malaysia – Jardiance Chronic Kidney Disease Indication
  
• NPRA Malaysia – Jardiance Heart Failure Indication
  
• NPRA Malaysia – Jardiance Registration Renewal
  
• European Medicines Agency – Jardiance Product Information
  
• NPRA Malaysia – Empagliflozin Tubulointerstitial Nephritis Safety Alert
  
• NPRA Malaysia – SGLT2 Inhibitor and Lithium Interaction
  

Product information last reviewed: 12 July 2026.